One of the biggest challenges of clinical trials is identifying the specific patient populations. This is a factor that has become even more critical with the rise of highly targeted oncology medicines. The solution: Artificial intelligence (AI) techniques which unify structured and unstructured clinical patient data for real-time accessibility.

To meet the demand of finding patients with highly specific mutational contexts of drug sensitivity for trial participation, TD2 turned to Deep 6 AI. Using a variety of AI and natural language processing (NLP) techniques, Deep 6 AI creates “patient graphs” from structured and unstructured data from every clinical event in a patient’s life and how those events relate.

For TD2, patients can be matched against clinical trial eligibility criteria in minutes, rather than the months it currently takes.

Hear from TD2 president and CEO, Stephen Gately and Deep 6 AI cofounder and CEO, Wout Brusselaers about the partnership and what the future holds for AI in drug development in Outsourcing-Pharma.

Efficient Data Management: One Way to Expedite the Clinical Development Proces

Debates on the safety and effectiveness of vaccines have captured the public’s attention recently. A vaccine is a preventative strategy for certain...

Read more +

The Clinical Trial Process Continues Amid COVID-19

It’s no secret that the top health concern on most Americans’ minds today is COVID-19 – a unprecedented disrupter like we’ve never seen...

Read more +

Technology Challenges and Trends in Clinical Trials

Cancer remains a leading cause of death among Americans with nearly two million newly diagnosed patients in 2018. As this trend continues, various...

Read more +

GET STARTED

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.